Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Biomarkers: FDA Working To Define 'Reasonably Likely To Predict' Standard

Executive Summary

CDER Director Woodcock says agency should write down its definition of a surrogate endpoint, but industry and academics will have to help with requirements for biomarker approval.


Related Content

Senate ‘Innovation’ Bill Being Narrowed With Year-End Committee Passage In Mind
FDA Patient Meeting On Huntington’s, Parkinson’s: No News Is Good News
Accelerated Approval For Biomarkers? FDA Considers “Limited Context of Use” To Shorten Qualification Process
Senate ‘Innovation’ Bill Being Narrowed With Year-End Committee Passage In Mind
PDUFA Budgeting: What Will Get Added, Subtracted – Or Multiplied By Cures?
‘Precision Medicine’ Gets R&D Funding Push In President’s Speech
Biomarker Development Meeting May Help Expand Accelerated Approval
Biomarkers In Orphan Studies Still Need Past Experience, FDA Says
PDUFA V: Final Recommendations Fund Proposals In Two Of Three Tiers